相关实验视频

Updated: Jul 2, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

miR-939-3p通过抑制BATF2诱导了肉瘤的扩散和不良预后

Wanwen Xu¹, Yinghui Huang², Zengjie Lei³

¹Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan, Hubei, China.

Frontiers in oncology

|February 29, 2024

概括

微RNA-939-3p通过降低瘤抑制剂基本氨酸拉链转录因子ATF-like 2 (BATF2) 的下调来促进肉瘤的进展. 抑制miR-939-3p或增加BATF2可能提供新的肉瘤治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因规则基因规则

背景情况:

肉瘤是一种罕见的,具有不良预后的侵袭性癌症.
瘤基因激活和瘤抑制器失活是肉瘤发展的关键因素.
基本氨酸拉链转录因子ATF-like 2 (BATF2) 是一种潜在的瘤抑制剂,但其在肉瘤中的作用尚未完全理解.

研究的目的:

研究微RNA (miR) -939-3p在肉瘤中的作用和机制.
为了确定miR-939-3p,BATF2和肉瘤进展之间的关系.
评估miR-939-3p和BATF2作为潜在的预后生物标志物和肉瘤治疗点.

主要方法:

对人类肉瘤组织和细胞系中BATF2和miR-939-3p表达的分析.
使用生物信息学,qPCR,西斑和细胞增殖试验.
雇佣过度表达,敲击,点突变和双露西法酶记者试验以阐明监管机制.

主要成果:

在肉瘤组织和细胞系中,BATF2表达显著下调,与患者预后不佳相关.
miR-939-3p在肉瘤上调和负调节了BATF2表达,通过直接结合其3' UTR.
miR-939-3p的过度表达促进了瘤细胞的增殖,而其抑制或BATF2恢复抑制了增殖.

结论:

miR-939-3p通过抑制瘤抑制剂BATF2的作用,在肉瘤中起到瘤性微RNA的作用.
miR-939-3p是一种用于肉瘤的新型预后生物标志物.
向miR-939-3p或增强BATF2表达是一种潜在的治疗策略.

关键词:

最常见的BATF2方法在 miR-939-3p 中使用.预后预后预后肉瘤肉瘤是一种肉瘤.治疗目标是治疗的目标.

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...